These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33605397)

  • 1. Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial.
    Guimarães MC; Guimarães TM; Hallak JE; Abrão J; Machado-de-Sousa JP
    Braz J Psychiatry; 2021; 43(5):484-493. PubMed ID: 33605397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
    Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
    Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
    Papakostas GI; Culpepper L; Fayyad RS; Musgnung J; Guico-Pabia CJ
    Int Clin Psychopharmacol; 2013 Nov; 28(6):312-21. PubMed ID: 23881185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial.
    Nagele P; Duma A; Kopec M; Gebara MA; Parsoei A; Walker M; Janski A; Panagopoulos VN; Cristancho P; Miller JP; Zorumski CF; Conway CR
    Biol Psychiatry; 2015 Jul; 78(1):10-18. PubMed ID: 25577164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.
    Dunlop BW; Parikh SV; Rothschild AJ; Thase ME; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M; Logan J; Traxler P; Li J; Johnson H; Greden JF
    BMC Psychiatry; 2019 Dec; 19(1):420. PubMed ID: 31881956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
    Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
    J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
    Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
    J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
    Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials.
    Tokuoka H; Takahashi H; Ozeki A; Kuga A; Yoshikawa A; Tsuji T; Wohlreich MM
    J Affect Disord; 2016 May; 196():171-80. PubMed ID: 26922146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
    Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
    Iwata N; Tourian KA; Hwang E; Mele L; Vialet C
    J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.
    Endicott J; Lam RW; Hsu MA; Fayyad R; Boucher M; Guico-Pabia CJ
    J Affect Disord; 2014 Sep; 166():307-14. PubMed ID: 25012446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
    Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
    J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial.
    Khadivi A; Shobeiri P; Momtazmaneh S; Samsami FS; Shalbafan M; Shirazi E; Akhondzadeh S
    Psychopharmacology (Berl); 2022 Feb; 239(2):551-559. PubMed ID: 35072758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.